{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:04:35Z","timestamp":1778828675518,"version":"3.51.4"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or sirolimus) against 30 Aspergillus isolates belonging to the most common species responsible for invasive aspergillosis in humans (Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus) was evaluated in vitro by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing. The interpretation of the results was performed based on the fractional inhibitory concentration index. The combination of isavuconazole with tacrolimus, cyclosporin A, or sirolimus, was synergistic for 56, 20, or 10% of the isolates, respectively. Interestingly synergy of the combination of isavuconazole with tacrolimus was also achieved for the majority of azole-resistant isolates of A. fumigatus, and for all A. niger isolates with isavuconazole minimal inhibitory concentrations \u2265 8 \u00b5g\/mL. Antagonistic interactions were never observed for any combination tested.<\/jats:p>","DOI":"10.3390\/jof6030103","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:47:46Z","timestamp":1594208866000},"page":"103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-1865","authenticated-orcid":false,"given":"Patrick","family":"Schwarz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany"},{"name":"Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-3830","authenticated-orcid":false,"given":"Eric","family":"Dannaoui","sequence":"additional","affiliation":[{"name":"Dynamyc Research Group (EA 7380), Facult\u00e9 de M\u00e9decine de Cr\u00e9teil, Universit\u00e9 Paris-Est-Cr\u00e9teil-Val-de-Marne, F-94010 Cr\u00e9teil, France"},{"name":"Unit\u00e9 de Parasitologie-Mycologie, H\u00f4pital Europ\u00e9en Georges-Pompidou, F-75015 Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Paris, 75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the path alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/cid\/civ103","article-title":"Invasive aspergillosis after kidney transplant: Case-control study","volume":"60","author":"Heylen","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: Incidence and prognosis","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s15010-008-8124-x","article-title":"A risk profile for invasive aspergillosis in liver transplant recipients","volume":"37","author":"Rosenhagen","year":"2009","journal-title":"Infection"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Kathuria, S., Xu, J., and Meis, J.F. (2013). Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog., 9.","DOI":"10.1371\/annotation\/4ffcf1da-b180-4149-834c-9c723c5dbf9b"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"Arendrup","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1128\/AAC.00185-11","article-title":"Azole resistance in Aspergillus fumigatus isolates from the artemis global surveillance study is primarily due to the TR\/L98H mutation in the cyp51A gene","volume":"55","author":"Lockhart","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115007","DOI":"10.1016\/j.diagmicrobio.2020.115007","article-title":"In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY antifungal surveillance program, 2017\u20132018","volume":"97","author":"Messer","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/jac\/dku259","article-title":"Multi-azole-resistant Aspergillus fumigatus in the environment in tanzania","volume":"69","author":"Chowdhary","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.V1061366","article-title":"Newer immunosuppressive drugs: A review","volume":"10","author":"Gummert","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","article-title":"Current and emerging strategies for the prevention of graft-versus-host disease","volume":"11","author":"Choi","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.45.11.3162-3170.2001","article-title":"Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR","volume":"45","author":"Cruz","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.44.1.143-149.2000","article-title":"Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin","volume":"44","author":"Cruz","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1128\/AAC.48.12.4922-4925.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/jis767","article-title":"Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis","volume":"207","author":"Lewis","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1128\/AAC.24.6.921","article-title":"Cyclosporin a inhibits Coccidioides immitis in vitro and in vivo","volume":"24","author":"Kirkland","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00184-09","article-title":"In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes","volume":"53","author":"Dannaoui","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkz102","article-title":"In vitro interactions between isavuconazole and tacrolimus, cyclosporin a or sirolimus against Mucorales","volume":"74","author":"Schwarz","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/JCM.39.2.478-484.2001","article-title":"Analysis of growth characteristics of filamentous fungi in different nutrient media","volume":"39","author":"Meletiadis","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin a and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0024-3205(95)02233-3","article-title":"Mechanism of action of the immunosuppressant rapamycin","volume":"58","author":"Dumont","year":"1996","journal-title":"Life Sci"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.44.3.739-746.2000","article-title":"Synergistic antifungal activities of bafilomycin a1, fluconazole, and the pneumocandin MK-0991\/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans","volume":"44","author":"Cruz","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jac\/dkm493","article-title":"In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves","volume":"61","author":"Li","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/42.6.747","article-title":"Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains","volume":"42","author":"Maesaki","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.44.9.2373-2381.2000","article-title":"Potent synergism of the combination of fluconazole and cyclosporine in candida albicans","volume":"44","author":"Marchetti","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.47.3.956-964.2003","article-title":"Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei","volume":"47","author":"Onyewu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/511438","article-title":"Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality","volume":"195","author":"Singh","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/AAC.01070-07","article-title":"In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods","volume":"52","author":"Sun","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkq020","article-title":"In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes","volume":"65","author":"Narreddy","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/myc.12909","article-title":"Antifungal combinations in mucorales: A microbiological perspective","volume":"62","author":"Schwarz","year":"2019","journal-title":"Mycoses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1128\/AAC.01510-15","article-title":"In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkg090","article-title":"Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species","volume":"51","author":"Kontoyiannis","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.48.5.1664-1669.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/jac\/dku549","article-title":"Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species","volume":"70","author":"Lamoth","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.4155\/fmc-2016-0050","article-title":"Targeting efflux pumps to overcome antifungal drug resistance","volume":"8","author":"Holmes","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1038\/s41467-019-12199-1","article-title":"Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents","volume":"10","author":"Juvvadi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e01627-18","DOI":"10.1128\/AAC.01627-18","article-title":"In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ndt\/gfm632","article-title":"Cinacalcet\u2019s effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients","volume":"23","author":"Falck","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.00990-07","article-title":"Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis","volume":"52","author":"Kontoyiannis","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/3\/103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:05Z","timestamp":1760176145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/3\/103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["jof6030103"],"URL":"https:\/\/doi.org\/10.3390\/jof6030103","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]}}}